Patient
SITE004-0194
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE004 (DEU) (Dr. Tanaka)
consented 2026-04-21
Adverse events
3
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 3
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-03-15 (study day 134); relationship: not assessed
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-11-08 (study day 7); relationship: RELATED
Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-11-04 (study day 3); relationship: not assessed; serious criteria: hospitalization
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.